Free shipping on all orders over $ 500

GNE-493

Cat. No. M1933
GNE-493 Structure
Size Price Availability Quantity
5mg USD 290 In stock
10mg USD 380 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

GNE-493 is a potent, selective and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor for the treatment of cancer. The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. GNE-493 is highly selective, demonstrate knock down of pathway markers in vivo, and is efficacious in xenograft models where the PI3K pathway is deregulated.

Protocol
Cell Experiment
Cell lines PC3 and MCF7.1 cells
Preparation method Antiproliferative cellular assays were conducted using PC3 and MCF7.1 human tumor cell lines provided by the ATCC or Genentech Research laboratories, respectively. MCF7.1 is an in vivo selected line developed at Genentech and originally derived from the parental human MCF7 breast cancer cell line (ATCC, Manassas, VA). Cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin, 10 mM HEPES, and 2 mM glutamine at 37 C under 5% CO2. MCF7.1 cells or PC3 cells were seeded in 384-well plates in media at 1000 cells/well or 3000 cells/well, respectively, and incubated overnight prior to the addition of compounds to a final DMSO concentration of 0.5% v/v. MCF7.1 cells and PC3 cells were incubated for 3 and 4 days, respectively, prior to the addition of CellTiter-Glo reagent (Promega) and reading of luminescence using an Analyst plate reader.
Concentrations 0~10 μM
Incubation time 3 and 4 days
Animal Experiment
Animal models Nu/nu(nude) female mice bearing PC3 prostate cancer xenografts
Formulation 0.5% methylcellulose/0.2% Tween-80
Dosages 10mg/kg daily for 14 days
Administration orally
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 372.44
Formula C17H20N6O2S
CAS Number 1033735-94-2
Purity >99%
Solubility DMSO 100 mg/mL
Storage at -20°C
References

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
Sutherlin DP, et al. J Med Chem. 2010 Feb 11;53(3):1086-97. PMID: 20050669.

Related PI3K Products
SF2523

SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.

IPI549

IPI549 is a potent and selective PI3Kγ Inhibitor with IC50 of 16 nM.

VPS34-IN1

Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.

Voxtalisib Analogue

Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.

PI-3065

PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: GNE-493 supplier, PI3K, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.